Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet in Pediatric SHPT on Dialysis
NCT01277510Phase 3Terminated
- Sponsor
- Amgen
- Start
- Jun 2011
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) comparing Placebo with Cinacalcet (2 arms). Primary endpoint: Percentage of Participants Achieving ≥ 30% Reduction in Mean iPTH From Baseline. Started Jun 2011; status: terminated.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01277510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01277510.